Effect of pravastatin on bleomycin-induced acute lung injury and pulmonary fibrosis

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 11, 2010, Pages 1055-1063

  Kim, Jin Woo ^a   Rhee, Chin Kook ^a   Kim, Tae Jung ^b   Kim, Yong Hyun ^a   Lee, Sang Haak ^a   Yoon, Hyung Kyu ^a   Kim, Seok Chan ^a   Lee, Sook Young ^a   Kwon, Soon Suk ^a   Kim, Kwan Hyung ^a   Kim, Young Kyoon ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Acute lung injury; Connective tissue growth factor; Pravastatin; Pulmonary fibrosis; Transforming growth factor 1

Indexed keywords

BLEOMYCIN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN D1; HYDROXYPROLINE; MESSENGER RNA; PRAVASTATIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CONNECTIVE TISSUE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HISTOPATHOLOGY; INFLAMMATION; LUNG FIBROSIS; LUNG INJURY; LUNG LAVAGE; MOUSE; NEUTROPHIL; NONHUMAN; TISSUE GROWTH;

ACUTE LUNG INJURY; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLEOMYCIN; BLOTTING, WESTERN; BRONCHOALVEOLAR LAVAGE FLUID; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIN D1; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HYDROXYPROLINE; MICE; MICE, INBRED C57BL; PRAVASTATIN; PULMONARY FIBROSIS; RESPIRATORY DISTRESS SYNDROME, ADULT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO GTP-BINDING PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 78049240567     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05431.x     Document Type: Article

References (53)

1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N. Engl. J. Med. 2000; 342: 1334-49.
2. Anonymous. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N. Engl. J. Med. 2000; 342: 1301-8.
3. Lamy M, Fallat RJ, Koeniger E et al. Pathologic features and mechanisms of hypoxemia in adult respiratory distress syndrome. Am. Rev. Respir. Dis. 1976; 114: 267-84.
4. Tomashefski JF Jr. Pulmonary pathology of the adult respiratory distress syndrome. Clin. Chest Med. 1990; 11: 593-619.
5. Hakkinen PJ, Morse CC, Martin FM, Dalbey WE, Haschek WM, Witschi HR. Potentiating effects of oxygen in lungs damaged by methylcyclopentadienyl manganese tricarbonyl, cadmium chloride, oleic acid, and antitumor drugs. Toxicol. Appl. Pharmacol. 1983; 67: 55-69.
6. Van Barneveld PW, Sleijfer DT, Van Der Mark TW et al. Natural course of bleomycin-induced pneumonitis. A follow-up study. Am. Rev. Respir. Dis. 1987; 135: 48-51.
7. Pittet JF, Griffiths MJ, Geiser T et al. TGF-beta is a critical mediator of acute lung injury. J. Clin. Invest. 2001; 107: 1537-44.
8. Azoulay E, Herigault S, Levame M et al. Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. Crit. Care Med. 2003; 31: 1442-8.
9. Yamagata T, Kinoshita K, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M. Effects of pravastatin in murine collagen-induced arthritis. Rheumatol. Int. 2007; 27: 631-9.
10. Li TS, Takahashi M, Suzuki R et al. Pravastatin improves remodeling and cardiac function after myocardial infarction by an antiinflammatory mechanism rather than by the induction of angiogenesis. Ann. Thorac. Surg. 2006; 81: 2217-25.
11. Watts KL, Sampson EM, Schultz GS, Spiteri MA. Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 2005; 32: 290-300.
12. Ou XM, Feng YL, Wen FQ et al. Simvastatin attenuates bleomycin-induced pulmonary fibrosis in mice. Chin. Med. J. (Engl). 2008; 121: 1821-9.
13. Caorsi C, Pineda F, Munoz C. Pravastatin immunomodulates IL-6 and C-reactive protein, but not IL-1 and TNF-alpha, in cardio-pulmonary bypass. Eur. Cytokine Netw. 2008; 19: 99-103.
14. Yao H, Mao L, Zhu J. Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury. Clin. Exp. Pharmacol. Physiol. 2006; 33: 793-7.
15. Bonniaud P, Margetts PJ, Ask K, Flanders K, Gauldie J, Kolb M. TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis. J. Immunol. 2005; 175: 5390-5.
16. Kothapalli D, Frazier KS, Welply A, Segarini PR, Grotendorst GR. Transforming growth factor beta induces anchorage-independent growth of NRK fibroblasts via a connective tissue growth factor-dependent signaling pathway. Cell Growth Differ. 1997; 8: 61-8.
17. Watts KL, Spiteri MA. Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004; 287: L1323-32.
18. Watts KL, Cottrell E, Hoban PR, Spiteri MA. RhoA signaling modulates cyclin D1 expression in human lung fibroblasts; implications for idiopathic pulmonary fibrosis. Respir. Res. 2006; 7: 88.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
20. Pugin J, Verghese G, Widmer MC, Matthay MA. The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. Crit. Care Med. 1999; 27: 304-12.
21. Pittet JF, Mackersie RC, Martin TR, Matthay MA. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am. J. Respir. Crit. Care Med. 1997; 155: 1187-205.
22. Fahy RJ, Lichtenberger F, McKeegan CB, Nuovo GJ, Marsh CB, Wewers MD. The acute respiratory distress syndrome: a role for transforming growth factor-beta 1. Am. J. Respir. Cell Mol. Biol. 2003; 28: 499-503.
23. Martin C, Papazian L, Payan MJ, Saux P, Gouin F. Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome. A study in mechanically ventilated patients. Chest 1995; 107: 196-200.
24. Anonymous. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2000; 283: 1995-2002.
25. Steinberg KP, Hudson LD, Goodman RB et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N. Engl. J. Med. 2006; 354: 1671-84.
26. Lee SY, Kim JS, Lee JM et al. Inhaled corticosteroid prevents the thickening of airway smooth muscle in murine model of chronic asthma. Pulm. Pharmacol. Ther. 2008; 21: 14-19.
27. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 1993; 48: 959-66.
28. Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. USA 1991; 88: 6642-6.
29. Dhainaut JF, Charpentier J, Chiche JD. Transforming growth factor-beta: a mediator of cell regulation in acute respiratory distress syndrome. Crit. Care Med. 2003; 31: S258-64.
30. Bogatkevich GS, Tourkina E, Abrams CS, Harley RA, Silver RM, Ludwicka-Bradley A. Contractile activity and smooth muscle alpha-actin organization in thrombin-induced human lung myofibroblasts. Am. J. Physiol. Lung Cell. Mol. Physiol. 2003; 285: L334-43.
31. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology 2004; 145: 5439-47.
32. Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology 1996; 34: 51-61.
33. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. 2001; 7: 687-92.
34. Davidson KG, Acton SM, Barr HA, Nicholas TE. Effect of lowering serum cholesterol on the composition of surfactant in adult rat lung. Am. J. Physiol. 1997; 272: L106-14.
35. Vockeroth D, Gunasekara L, Amrein M, Possmayer F, Lewis JF, Veldhuizen RA. Role of cholesterol in the biophysical dysfunction of surfactant in ventilator-induced lung injury. Am. J. Physiol. Lung Cell. Mol. Physiol. 2010; 298: L117-25.
36. Guthmann F, Harrach-Ruprecht B, Looman AC, Stevens PA, Robenek H, Rstow B. Interaction of lipoproteins with type II pneumocytes in vitro: morphological studies, uptake kinetics and secretion rate of cholesterol. Eur. J. Cell Biol. 1997; 74: 197-207.
37. Hass MA, Longmore WJ. Surfactant cholesterol metabolism of the isolated perfused rat lung. Biochim. Biophys. Acta 1979; 573: 166-74.
38. McCrae KC, Weltman B, Alyward S et al. The effect of elevated dietary cholesterol on pulmonary surfactant function in adolescent mice. Pediatr. Pulmonol. 2008; 43: 426-34.
39. Shyamsundar M, McKeown ST, O'Kane CM et al. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am. J. Respir. Crit. Care Med. 2009; 179: 1107-14.
40. Anonymous. Acute lung injury and the acute respiratory distress syndrome in Ireland: a prospective audit of epidemiology and management. Crit. Care 2008; 12: R30.
41. Taylor RW, Zimmerman JL, Dellinger RP et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 2004; 291: 1603-9.
42. Rossaint R, Falke KJ, Lpez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N. Engl. J. Med. 1993; 328: 399-405.
43. Troncy E, Collet JP, Shapiro S et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am. J. Respir. Crit. Care Med. 1998; 157: 1483-8.
44. Michael JR, Barton RG, Saffle JR et al. Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am. J. Respir. Crit. Care Med. 1998; 157: 1372-80.
45. Khammash H, Perlman M, Wojtulewicz J, Dunn M. Surfactant therapy in full-term neonates with severe respiratory failure. Pediatrics 1993; 92: 135-9.
46. Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996; 97: 48-52.
47. Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991; 87: 101-7.
48. Lotze A, Knight GR, Martin GR et al. Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation. J. Pediatr. 1993; 122: 261-8.
49. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group. J. Pediatr. 1998; 132: 40-7.
50. Luchetti M, Ferrero F, Gallini C et al. Multicenter, randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Pediatr. Crit. Care Med. 2002; 3: 261-8.
51. Anzueto A, Baughman RP, Guntupalli KK et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N. Engl. J. Med. 1996; 334: 1417-21.
52. Spragg RG, Lewis JF, Wurst W et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am. J. Respir. Crit. Care Med. 2003; 167: 1562-6.
53. Meduri GU, Golden E, Freire AX et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007; 131: 954-63.